Hylomorph secures CHF 5.2 million series-B round
03.12.2021
The clinical-stage startup aims to minimise post-surgical complications in medical implants. Proceeds from its CHF 5.2 series B investment CHF 0.9 Million non-dilutive funding will support the company in obtaining the FDA and CE mark approval for its product portfolio, beginning with the Hylomate.